Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
Healthcare
$14.10 +1.42%
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
52W Low $4.98High $41.42
Volume 0.21M
Average 0.74M
Income Statement
Follow revenue through to earnings.
Revenue
$27.47M
FY 2025 · Annual
+195.7% YoYOperating Income
-$26.52M
FY 2025 · Annual
Net Income
-$26.60M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Cost of Revenue | (1.78M) | 0 | 38.1M | 0 | 0 |
| Gross Profit | 16.72M | 1.25M | (32.61M) | 9.29M | 27.47M |
| Gross Margin | 111.9% | 100.0% | -593.9% | 100.0% | 100.0% |
| Research & Development | 41.35M | 38.58M | 40.8M | 36.3M | 37.74M |
| Selling, General & Admin | 17.31M | 16.17M | 16.68M | 14.59M | 16.24M |
| Operating Expenses | 60.43M | 54.47M | 19.54M | 50.79M | 53.99M |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 3.48M |
| EBITDA | (45.44M) | (50.49M) | (46.05M) | (37.53M) | (22.27M) |
| EBITDA Margin | -304.1% | -4055.5% | -838.8% | -404.1% | -81.1% |
| Operating Income | (43.71M) | (53.23M) | (52.15M) | (41.5M) | (26.52M) |
| Operating Margin | -292.6% | -4275.1% | -949.9% | -446.9% | -96.6% |
| Interest Income | 45.9K | 928.24K | 2.66M | 1.62M | 807K |
| Interest Expense | 0 | 713.82K | 1.25M | 796K | 357K |
| Other Income / Expenses | 45.9K | 215K | 1.42M | 826K | 419K |
| Income Before Tax | (43.67M) | (53.01M) | (50.73M) | (40.67M) | (26.1M) |
| Pre-Tax Margin | -292.3% | -4257.8% | -924.1% | -438.0% | -95.0% |
| Income Tax Expense | 495K | 0 | 0 | 0 | 500K |
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Net Margin | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (Basic) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| EPS (Diluted) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| 1.04M | 1.19M | 1.53M | 1.88M | 3.16M | |
| 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
CUE Earnings Waterfall · TTM
NASDAQ:CUE · Revenue to Net Income
Key Ratios
EPS$-5.53
Gross Margin99.1%
Net Margin-179.4%
P/E Ratio-0.2
P/S Ratio15.8
Analysis
$32.7M of revenue converted into -$19.5M of net income for the selected period. Gross margin is 99.1% and net margin is -179.4%, showing how much revenue survives after costs and taxes. EPS is $-5.53, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 8, 2026 |
How much revenue does CUE generate?
Cue Biopharma, Inc. (CUE) reported $27.47M of revenue in fiscal 2025.
Is CUE profitable?
Cue Biopharma, Inc. (CUE) reported -$26.60M of net income, with a net margin of -96.9%.
Continue the stock analysis
Jump to another research area for this company.